Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation

From General Health Information to Targeted Risk Assessment

For decades, public health communication has centered on general health and science information, emphasizing broad wellness principles and disease prevention. This foundational approach has served to educate populations on lifestyle factors, environmental influences, and the importance of medical vigilance. Within this legacy, the role of pharmaceutical agents and their potential long-term effects has been a recurring theme, though typically framed in terms of patient safety and therapeutic benefit. As scientific inquiry deepens, attention has increasingly turned toward specific exposures and their nuanced relationships with health outcomes. One such area of focus involves the immune checkpoint inhibitor Avelumab, approved for certain cancers, and emerging questions about its association with Merkel cell carcinoma risk. This pivot from general health context to a more targeted occupational exposure concern reflects a natural evolution in risk assessment. In industrial and healthcare settings, workers may encounter Avelumab through manufacturing, administration, or accidental exposure, prompting a need to understand whether such contact could influence carcinogenic processes. The transition from broad health literacy to this specialized inquiry underscores the importance of examining how therapeutic compounds, when present in occupational environments, may carry implications distinct from their intended clinical use. This shift demands careful consideration of exposure pathways and population-level surveillance.

Understanding Avelumab and Its Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus; approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic disease (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of five patients with metastatic MCC refractory to avelumab who were later treated with combined ipilimumab and nivolumab were collected and evaluated; three out of five patients responded to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly investigated ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Causation and Risk: What the Evidence Shows

Regarding causation-related considerations, avelumab is approved specifically for the treatment of metastatic MCC, meaning that its use is indicated in patients who already have the disease. The evidence does not indicate that avelumab causes MCC; rather, it is a therapeutic agent used to treat MCC. The risk narrative therefore centers on the adequacy of warnings regarding avelumab's efficacy and safety in the context of MCC. The JAVELIN Merkel 200 trial provided the basis for approval, with confirmed objective responses in approximately one-third of patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the evidence also highlights that a substantial proportion of patients do not respond or develop immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, alternative treatment options such as combined ipilimumab and nivolumab may be considered, though data are limited to small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/). The timeline between exposure to avelumab and documented harm is not explicitly detailed in the provided evidence. However, the evidence indicates that immune-related adverse events can occur during treatment, and that approximately 50% of patients may not respond or may develop such events (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment of metastatic MCC with anti-PD-1/PD-L1 immune checkpoint inhibitors, including avelumab, shows better overall response rates and longer duration of responses compared with conventional chemotherapy, but the risk of progression or adverse events remains significant (https://pubmed.ncbi.nlm.nih.gov/34445385/). In summary, the evidence supports that avelumab is an approved and effective treatment for metastatic MCC, but it is not a cause of MCC. The primary risks associated with avelumab in this context are lack of response, disease progression, and immune-related adverse events. Warnings regarding these risks are inherent in the prescribing information and clinical trial data. For affected patients, considerations include the potential need for alternative therapies if avelumab fails, as well as monitoring for immune-related adverse events. The timeline for harm is generally during or after treatment, though specific temporal data are not provided in the evidence.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the evidence does not indicate that avelumab causes Merkel cell carcinoma. Avelumab is a therapeutic agent approved for the treatment of metastatic MCC, meaning it is used in patients who already have the disease. The primary risks associated with avelumab are lack of response, disease progression, and immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/34445385/).

What are the main risks of avelumab treatment for Merkel cell carcinoma?

The main risks include lack of response (approximately 50% of patients may not respond), disease progression, and immune-related adverse events. These risks are documented in clinical trials and prescribing information (https://pubmed.ncbi.nlm.nih.gov/34445385/).

What alternative treatments are available if avelumab fails?

For patients refractory to avelumab, combined ipilimumab and nivolumab may be considered, though data are limited to small retrospective studies (https://pubmed.ncbi.nlm.nih.gov/33439294/). Other options may include clinical trials or alternative immune checkpoint inhibitors.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.